Basic Information
| RNALocate ID: | RLID:11003904 |
| RNA Symbol: | hsa-miR-330-5p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-330-5p |
| RNA ID: | miRBase:MIMAT0004693 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23663360 |
| Tissue/Cell Line: | Plasma |
| Method: | Next-generation RNA sequencing |
| Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:11003903 | Exosome | HCC tissues | 30542726 |
| RLID-D:11000665 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells | |
| RLID-D:11001536 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-330-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-40598 |
| MNDR | hsa-miR-330-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-40599 |
| MNDR | hsa-miR-330-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-40600 |
| MNDR | hsa-miR-330-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-40601 |
| MNDR | hsa-miR-330-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-40602 |
| MNDR | hsa-miR-330-5p | Her2-receptor positive breast cancer | MNDR-E-MI-40603 |
| MNDR | hsa-miR-330-5p | Prostate cancer | MNDR-E-MI-40604 |
| MNDR | hsa-miR-330-5p | Gastric cancer | MNDR-E-MI-40605 |
| MNDR | hsa-miR-330-5p | Alzheimer disease | MNDR-E-MI-40606 |
| MNDR | hsa-miR-330-5p | Huntington disease | MNDR-E-MI-40607 |
| MNDR | hsa-miR-330-5p | Lung cancer | MNDR-E-MI-40608 |
| MNDR | hsa-miR-330-5p | Parkinson disease | MNDR-E-MI-40609 |
| MNDR | hsa-miR-330-5p | Breast cancer | MNDR-E-MI-40610 |
| MNDR | hsa-miR-330-5p | Pancreatic cancer | MNDR-E-MI-40611 |
| MNDR | hsa-miR-330-5p | Colon cancer | MNDR-E-MI-40612 |
| MNDR | hsa-miR-330-5p | Colon adenocarcinoma | MNDR-E-MI-40613 |
| MNDR | hsa-miR-330-5p | Relapsing-remitting multiple sclerosis | MNDR-E-MI-40614 |
| MNDR | hsa-miR-330-5p | Familial ovarian cancer | MNDR-E-MI-40615 |
| MNDR | hsa-miR-330-5p | Prostate adenocarcinoma | MNDR-E-MI-40616 |
| MNDR | hsa-miR-330-5p | Carcinoma ductal breast | MNDR-E-MI-40617 |
| MNDR | hsa-miR-330-5p | Glioblastoma | MNDR-E-MI-40618 |
| MNDR | hsa-miR-330-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-40619 |
| MNDR | hsa-miR-330-5p | Osteosarcoma | MNDR-E-MI-40620 |
| MNDR | hsa-miR-330-5p | Middle cerebral artery infarction | MNDR-E-MI-40621 |
| MNDR | hsa-miR-330-5p | Lung squamous cell carcinoma | MNDR-E-MI-40622 |
| MNDR | hsa-miR-330-5p | Non-small cell lung cancer | MNDR-E-MI-40623 |
| MNDR | hsa-miR-330-5p | Lung adenocarcinoma | MNDR-E-MI-40624 |
| MNDR | hsa-miR-330-5p | Bladder urothelial carcinoma | MNDR-E-MI-40625 |
| MNDR | hsa-miR-330-5p | Pancreatic adenocarcinoma | MNDR-E-MI-40626 |
| MNDR | hsa-miR-330-5p | Carcinoma renal cell | MNDR-E-MI-40627 |
| MNDR | hsa-miR-330-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-40628 |
| MNDR | hsa-miR-330-5p | Renal clear cell carcinoma | MNDR-E-MI-40629 |
| MNDR | hsa-miR-330-5p | Esophagus adenocarcinoma | MNDR-E-MI-40630 |
| MNDR | hsa-miR-330-5p | Cholangiocarcinoma | MNDR-E-MI-40631 |
| MNDR | hsa-miR-330-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-40632 |
| MNDR | hsa-miR-330-5p | Breast invasive carcinoma | MNDR-E-MI-40633 |
| MNDR | hsa-miR-330-5p | Hepatocellular carcinoma | MNDR-E-MI-40634 |
| MNDR | hsa-miR-330-5p | Familiar ovarian carcinoma | MNDR-E-MI-40635 |
| MNDR | hsa-miR-330-5p | Barrett's adenocarcinoma | MNDR-E-MI-40636 |
| MNDR | hsa-miR-330-5p | Neuromyelitis optica | MNDR-E-MI-40637 |
| MNDR | hsa-miR-330-5p | Skin cutaneous melanoma | MNDR-E-MI-40638 |
| MNDR | hsa-miR-330-5p | Skin melanoma | MNDR-E-MI-40639 |
| MNDR | hsa-miR-330-5p | Colorectal cancer | MNDR-E-MI-40640 |
| MNDR | hsa-miR-330-5p | Nasopharynx carcinoma | MNDR-E-MI-40641 |
| MNDR | hsa-miR-330-5p | Nasopharyngeal cancer | MNDR-E-MI-40642 |
| MNDR | hsa-miR-330-5p | Barrett's carcinogenesis | MNDR-E-MI-40643 |
| MNDR | hsa-miR-330-5p | Breast cancer her3+ negative | MNDR-E-MI-40644 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | CCND1 | Homo sapiens | RR00294821 |
TOP